A Phase 2/3 interventional study of LY2189265 and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 99 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-04-20.
Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 3 that started in 2008, is the only one in phase 2/3, and was the 2nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,202 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 18th largest by enrollment of the 232 interventional ones that give a count, is one of 8 that started in 2008, is one of 2 in phase 2/3, and was the 32nd registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
This is a double blind study designed to select 1 or 2 LY2189265 doses for evaluation in Phase 3 studies (dose-finding portion) and to evaluate efficacy and safety of selected doses of LY2189265 in comparison to Sitagliptin (100 milligrams) up to 104 weeks and Placebo up to 26 weeks in participants with type 2 diabetes mellitus on Metformin (confirmatory, Phase 3 portion). The primary objective is to show non-inferiority of the higher LY2189265 dose (if 2 doses are selected) to Sitagliptin with respect to change in glycosylated hemoglobin (HbA1c) at 52 weeks. The final endpoint is 104 weeks.
Participants are randomized to receive Placebo, Sitagliptin, or 1 of 7 initial LY2189265 doses until a dose decision is made based on quantitative analysis of the benefits and risks of each LY2189265 dose. A clinical utility index (CUI) that applies predicted values for change from baseline in HbA1c at 12 months and change from baseline in weight, diastolic blood pressure, and pulse rate at 6 months for each LY2189265 dose will be used toward this end. After the dose decision, participants in the selected LY2189265 arms and the comparator arms (Sitagliptin and Placebo/Sitagliptin arms) will continue the study, and additional participants will be randomized to the selected and comparator arms. Regardless of the timing of randomization relative to the dose decision point, all participants in the selected and comparator arms are planned to receive treatment for 104 weeks; participants in the Placebo/Sitagliptin arm will receive Placebo treatment for 26 weeks followed by Sitagliptin 100 mg for 78 weeks for blinding purposes only, and participants in the selected and Sitagliptin arms will receive the same treatment for 104 weeks. All participants will remain blinded to their study treatment throughout the study. Participants in the non-selected arms will discontinue from the study after the dose decision
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin
LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin
LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin
LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin
LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin
LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin
LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks
Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin
Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks
Drug: Sitagliptin · Drug: Placebo solution · Drug: Metformin
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks Placebo: tablet, administered orally, once daily for 26 weeks Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks
Drug: Placebo solution · Drug: Placebo tablet · Drug: Metformin
Also known as: Dulaglutide, Trulicity
Glycosylated Hemoglobin (HbA1c) Change From Baseline
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, 52 weeks
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point
Change from baseline in HbA1c was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.
Time frame: Baseline up to 27.4 weeks
Glycosylated Hemoglobin (HbA1c) Change From Baseline
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, 26 weeks, 104 weeks
Durability of Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Durability of effect on HbA1c was assessed by comparing the differences in mean change from baseline in HbA1c at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline HbA1c data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 13, 26, 52, and 104 weeks
Fasting Blood Glucose Change From Baseline
Least squares (LS) means of change from baseline were calculated using mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 104 weeks
Fasting Insulin Change From Baseline
Least squares (LS) means of change from baseline fasting insulin data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 104 weeks
Change From Baseline in Body Weight at Dose Decision Point
Change from baseline in body weight was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.
Time frame: Baseline up to 27.4 weeks
Body Weight Change From Baseline
Least squares (LS) means of change from baseline body weight were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 104 weeks
Durability of Change From Baseline Body Weight
Durability of effect on body weight was assessed by comparing the differences in mean change from baseline in body weight at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline body weight data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 13, 26, 52, and 104 weeks
Waist Circumference Change From Baseline
Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 104 weeks
Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%
The percentage of participants achieving HbA1c levels \<7.0% and ≤6.5% was analyzed using a logistic regression model and last observation carried forward (LOCF) imputation with baseline, country, and treatment as factors included in the model.
Time frame: Baseline, 26, 52, and 104 weeks
Incidence of Hypoglycemic Episodes
Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of participants with self-reported hypoglycemic events is summarized cumulatively.
Time frame: Baseline through 26 and 104 weeks
Rate of Hypoglycemic Episodes
Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of HE is summarized cumulatively.
Time frame: Baseline through 26 and 104 weeks
Beta Cell Function and Insulin Sensitivity (HOMA2)
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-%B and HOMA2-%S were set at 100%. Least squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 104 weeks
Number of Participants With Treatment-emergent Adverse Events at 26 Weeks
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks
Number of Participants With Treatment-emergent Adverse Events at 52 Weeks
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Number of Participants With Treatment-emergent Adverse Events at 104 Weeks
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 104 weeks
Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 26 Weeks
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).
Time frame: Baseline through 26 weeks
Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 52 Weeks
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR) .
Time frame: Baseline through 52 weeks
Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 104 Weeks
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).
Time frame: Baseline through 104 weeks
Number of Participants With Treatment-emergent Abnormal Lipid Tests
The number of participants with treatment-emergent abnormal lipid test (cholesterol, high density lipoprotein cholesterol \[HDL-C\], low density lipoprotein cholesterol \[LDL-C\], and triglycerides \[TG\]) results (defined as lipid test abnormalities that first occurred after baseline) is summarized cumulatively.
Time frame: Baseline through 26 and 104 weeks
Change From Baseline in Pulse Rate at Dose Decision Point
Sitting pulse rate was measured at the time that the dose decision was made (dose decision point). Change from baseline in pulse rate was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.
Time frame: Baseline up to 27.4 weeks
Change From Baseline in Blood Pressure at Dose Decision Point
Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at the dose decision point. Change from baseline in DBP was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the time of the decision point was 27.4 weeks.
Time frame: Baseline up to 27.4 weeks
Change From Baseline in Pulse Rate
Sitting and standing pulse rate were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as covariate.
Time frame: Baseline, 26 weeks, 104 weeks
Change From Baseline in Blood Pressure
Sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks, 104 weeks
Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia-corrected QT (QTcF) and PR Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks, 104 weeks
Participant-reported Outcomes, Impact of Weight on Quality of Life-Lite (IWQoL-Lite)
The Impact of Weight on Quality of Life-Lite (IWQoL-Lite questionnaire) is an obesity-specific, 31-item questionnaire designed to measure the impact of weight on participants' quality of life. Items are scored on a 5-point numeric rating scale where 5 = "always true" and 1 = "never true". Items are summed into 6 scales (physical function \[11 items\], self-esteem \[7 items\], sexual life \[4 items\], public distress \[5 items\], work \[4 items\], and total score \[31 items\]) based on the average for the valid responses on that scale multiplied by the number of items on that scale (rounded to the nearest whole integer). Higher scores indicate lower levels of functioning (negative effects). Scores are linearly transformed to a 0 to 100 scale.
Time frame: Baseline, 52 weeks, and 104 weeks
Participant-reported Outcomes, EQ-5D
The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts. The first part allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a three level scale of 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the questionnaire consists of a 100-millimeter visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline, 52 weeks, and 104 weeks
Resource Utilization
The number of visits to the emergency room (ER) is summarized cumulatively.
Time frame: Baseline through 52 and 104 weeks
Pharmacokinetics of LY2189265: Area Under the Concentration-Time Curve
Pharmacokinetic (PK) parameter estimates from LY2189265 concentration data were obtained using a 2-compartment population PK model with first order absorption. Area under the plasma-concentration curve from 0 to 168 hours, steady state (AUC0-168h, ss) of LY2189265 is summarized.
Time frame: Baseline through 52 weeks
Antibodies to LY2189265
The number of participants with postbaseline detection of treatment-emergent antidrug LY2189265 antibodies (ADA) is summarized.
Time frame: Baseline through 104 weeks
Number of Participants With Adjudicated Pancreatitis at 104 Weeks
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 104 weeks
Number of Participants With Adjudicated Cardiovascular Events at 104 Weeks
Data on any new cardiovascular (CV) event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 104 weeks
| Milestone | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin |
|---|---|---|---|---|---|---|---|---|---|
| Started | 15 | 30 | 304 | 10 | 302 | 25 | 24 | 315 | 177 |
| Received at least 1 dose of study drug | 15 | 30 | 304 | 10 | 302 | 25 | 24 | 315 | 177 |
| Entered study before dose decision point | 15 | 30 | 25 | 10 | 21 | 25 | 24 | 42 | 38 |
| Completed up to dose decision point | 8 | 25 | 24 | 8 | 21 | 21 | 23 | 42 | 34 |
| Entered study after dose decision point | 0 | 0 | 279 | 0 | 281 | 0 | 0 | 273 | 139 |
| Completed 26-week visit | 0 | 0 | 258 | 2 | 268 | 2 | 2 | 270 | 124 |
| Completed 52-week visit | 0 | 0 | 238 | 0 | 243 | 0 | 0 | 238 | 112 |
| Completed | 0 | 0 | 192 | 0 | 184 | 0 | 0 | 186 | 95 |
| Not completed | 15 | 30 | 112 | 10 | 118 | 25 | 24 | 129 | 82 |
| Withdrew: Entry criteria not met | 0 | 0 | 5 | 0 | 3 | 1 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 13 | 0 | 11 | 1 | 0 | 9 | 4 |
| Withdrew: Withdrawal by subject | 2 | 1 | 18 | 0 | 24 | 2 | 0 | 36 | 21 |
| Withdrew: Physician decision | 0 | 0 | 4 | 1 | 11 | 0 | 0 | 9 | 9 |
| Withdrew: Adverse event | 4 | 4 | 63 | 1 | 64 | 0 | 1 | 65 | 39 |
| Withdrew: Protocol violation | 0 | 0 | 4 | 0 | 3 | 0 | 0 | 3 | 1 |
| Withdrew: Sponsor decision, arm discontinued | 8 | 25 | 0 | 8 | 0 | 21 | 23 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 4 | 6 |
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.
| percentage of HbA1c | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin |
|---|---|---|---|
| Glycosylated Hemoglobin (HbA1c) Change From Baseline | -1.10 ± 0.06 | -0.87 ± 0.06 | -0.39 ± 0.06 |
Change from baseline in HbA1c was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.
| percentage of HbA1c | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point | -1.09 ± 0.77 | -1.25 ± 0.68 | -1.49 ± 1.12 | -0.98 ± 0.47 | -1.02 ± 0.99 | -0.94 ± 0.65 | -0.70 ± 0.49 | -0.76 ± 0.86 | -0.06 ± 0.64 |
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.
| percentage of HbA1c | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| 26 Weeks | -1.22 ± 0.05 | -1.01 ± 0.06 | -0.61 ± 0.05 | 0.03 ± 0.07 |
| 104 Weeks | -0.99 ± 0.06 | -0.71 ± 0.07 | -0.32 ± 0.06 | NA ± NA |
Durability of effect on HbA1c was assessed by comparing the differences in mean change from baseline in HbA1c at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline HbA1c data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| percentage of HbA1c | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| 26 Weeks Versus 13 Weeks (n=269, 269, 276, 136) | -0.03 ± 0.04 | 0.02 ± 0.04 | 0.00 ± 0.04 | -0.14 ± 0.05 |
| 52 Weeks Versus 26 Weeks (n=245, 254, 250) | 0.14 ± 0.05 | 0.16 ± 0.05 | 0.24 ± 0.05 | NA ± NA |
| 104 Weeks Versus 52 Weeks (n=194, 191, 190) | 0.13 ± 0.06 | 0.16 ± 0.06 | 0.09 ± 0.06 | NA ± NA |
Least squares (LS) means of change from baseline were calculated using mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| millimoles per liter (mmol/L) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| 26 Weeks (n=265, 271, 276, 135) | -2.38 ± 0.12 | -1.97 ± 0.12 | -0.97 ± 0.11 | -0.49 ± 0.16 |
| 52 Weeks (n=239, 247, 244) | -2.38 ± 0.13 | -1.63 ± 0.13 | -0.90 ± 0.13 | NA ± NA |
| 104 Weeks (n=190, 187, 181) | -1.99 ± 0.15 | -1.39 ± 0.15 | -0.47 ± 0.15 | NA ± NA |
Least squares (LS) means of change from baseline fasting insulin data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| picomoles per liter (pmol/L) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| 26 Weeks (n=238, 249, 230, 115) | 11.59 ± 6.57 | 10.15 ± 6.51 | 8.48 ± 6.68 | -6.92 ± 9.24 |
| 52 Weeks (n=207, 218, 200) | 10.57 ± 5.95 | 12.95 ± 5.88 | 4.18 ± 6.01 | NA ± NA |
| 104 Weeks (n=187, 200, 183) | 11.36 ± 7.58 | 21.56 ± 7.40 | 0.29 ± 7.64 | NA ± NA |
Change from baseline in body weight was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.
| kilograms (kg) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight at Dose Decision Point | -3.32 ± 3.37 | -2.15 ± 1.97 | -2.12 ± 1.93 | -2.23 ± 1.63 | -1.17 ± 2.30 | -1.53 ± 1.88 | -0.85 ± 1.47 | -0.43 ± 1.78 | -0.56 ± 1.69 |
Least squares (LS) means of change from baseline body weight were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline as a covariate.
| kilograms (kg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| 26 Weeks | -3.18 ± 0.18 | -2.63 ± 0.19 | -1.46 ± 0.18 | -1.47 ± 0.24 |
| 52 Weeks | -3.03 ± 0.22 | -2.60 ± 0.23 | -1.53 ± 0.22 | NA ± NA |
| 104 Weeks | -2.88 ± 0.25 | -2.39 ± 0.26 | -1.75 ± 0.25 | NA ± NA |
Durability of effect on body weight was assessed by comparing the differences in mean change from baseline in body weight at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline body weight data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| kilograms (kg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| 26 Weeks Versus 13 Weeks (n=271, 278, 282, 138) | -0.53 ± 0.14 | -0.57 ± 0.14 | -0.42 ± 0.13 | -0.37 ± 0.18 |
| 52 Weeks Versus 26 Weeks (n=246, 255, 253) | 0.17 ± 0.18 | 0.06 ± 0.18 | -0.04 ± 0.18 | NA ± NA |
| 104 Weeks Versus 26 Weeks (n=197, 192, 191) | 0.42 ± 0.23 | 0.32 ± 0.24 | -0.39 ± 0.23 | NA ± NA |
Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| centimeters (cm) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| 26 Weeks (n=266, 273, 277, 138) | -2.89 ± 0.24 | -1.78 ± 0.24 | -1.45 ± 0.24 | -1.20 ± 0.32 |
| 52 Weeks (n=238, 250, 247) | -2.91 ± 0.29 | -2.05 ± 0.29 | -1.45 ± 0.29 | NA ± NA |
| 104 Weeks (n=192, 189, 188) | -2.57 ± 0.35 | -1.75 ± 0.35 | -1.20 ± 0.35 | NA ± NA |
The percentage of participants achieving HbA1c levels \<7.0% and ≤6.5% was analyzed using a logistic regression model and last observation carried forward (LOCF) imputation with baseline, country, and treatment as factors included in the model.
| percentage of participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| <7.0% at 26 Weeks | 60.9 | 55.2 | 37.8 | 21.0 |
| <7.0% at 52 Weeks | 57.6 | 48.8 | 33.0 | NA |
| <7.0% at 104 Weeks | 54.3 | 44.8 | 31.1 | NA |
| ≤6.5% at 26 Weeks | 46.7 | 31.0 | 21.8 | 12.5 |
| ≤6.5% at 52 Weeks | 41.7 | 29.0 | 19.2 | NA |
| ≤6.5% at 104 Weeks | 39.1 | 24.2 | 14.1 | NA |
Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of participants with self-reported hypoglycemic events is summarized cumulatively.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| Severe HE, 26 Weeks | 0 | 0 | 0 | 0 |
| Severe HE, 104 Weeks | 0 | 0 | 0 | NA |
| Documented Symptomatic HE, 26 Weeks | 17 | 8 | 10 | 2 |
| Documented Symptomatic HE, 104 Weeks | 33 | 19 | 18 | NA |
| Asymptomatic HE, 26 Weeks | 5 | 5 | 0 | 0 |
| Asymptomatic HE, 104 Weeks | 9 | 9 | 3 | NA |
| Nocturnal HE, 26 Weeks | 7 | 5 | 2 | 0 |
| Nocturnal HE, 104 Weeks | 14 | 13 | 10 | NA |
| Probable HE, 26 Weeks | 5 | 0 | 2 | 0 |
| Probable HE, 104 Weeks | 6 | 2 | 6 | NA |
Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of HE is summarized cumulatively.
| episodes per participant per year | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| Severe HE, 26 Weeks | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Severe HE, 104 Weeks | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | NA ± NA |
| Documented Symptomatic HE, 26 Weeks | 0.3 ± 1.5 | 0.1 ± 0.9 | 0.1 ± 0.7 | 0.1 ± 0.9 |
| Documented Symptomatic HE, 104 Weeks | 0.2 ± 0.9 | 0.2 ± 1.9 | 0.2 ± 1.4 | NA ± NA |
| Asymptomatic HE, 26 Weeks | 0.1 ± 0.8 | 0.1 ± 0.5 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Asymptomatic HE, 104 Weeks | 0.1 ± 0.4 | 0.0 ± 0.2 | 0.0 ± 0.1 | NA ± NA |
| Nocturnal HE, 26 Weeks | 0.1 ± 0.9 | 0.1 ± 0.6 | 0.0 ± 0.4 | 0.0 ± 0.0 |
| Nocturnal HE, 104 Weeks | 0.1 ± 0.5 | 0.0 ± 0.2 | 0.1 ± 0.5 | NA ± NA |
| Probable Symptomatic HE, 26 Weeks | 0.0 ± 0.4 | 0.0 ± 0.0 | 0.0 ± 0.2 | 0.0 ± 0.0 |
| Probable Symptomatic HE, 104 Weeks | 0.0 ± 0.1 | 0.0 ± 0.0 | 0.0 ± 0.1 | NA ± NA |
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-%B and HOMA2-%S were set at 100%. Least squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| HOMA2-% | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| HOMA2-%B, 26 Weeks (n=206, 226, 206, 84) | 32.28 ± 2.67 | 26.98 ± 2.60 | 10.81 ± 2.66 | 1.60 ± 4.02 |
| HOMA2-%B, 52 Weeks (n=188, 198, 180) | 33.57 ± 2.51 | 22.30 ± 2.47 | 6.66 ± 2.53 | NA ± NA |
| HOMA2-%B, 104 Weeks (n=148, 154, 134) | 30.89 ± 3.05 | 19.11 ± 3.00 | 1.47 ± 3.15 | NA ± NA |
| HOMA2-%S, 26 Weeks (n=206, 226, 206, 84) | 5.75 ± 2.34 | 0.78 ± 2.28 | 2.29 ± 2.33 | 9.82 ± 3.50 |
| HOMA2-%S, 52 Weeks (n=188, 198, 180) | 4.69 ± 2.35 | 2.28 ± 2.32 | 4.25 ± 2.37 | NA ± NA |
| HOMA2-%S, 104 Weeks (n=148, 154, 134) | 3.82 ± 3.00 | -0.12 ± 2.95 | 5.61 ± 3.11 | NA ± NA |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events at 26 Weeks | 208 | 204 | 185 | 111 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events at 52 Weeks | 9 | 20 | 233 | 8 | 231 | 15 | 10 | 219 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events at 104 Weeks | 259 | 255 | 242 |
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| Alkaline Phosphatase (n=276, 258, 281, 162) | 9 | 3 | 12 | 3 |
| ALT/SGPT (n=232, 237, 244, 128) | 18 | 24 | 25 | 8 |
| Amylase Pancreatic, High (n=283, 277, 295, 160) | 54 | 55 | 42 | 18 |
| Amylase Total (n=266, 265, 277, 143) | 33 | 33 | 27 | 13 |
| AST/SGOT (n=273, 269, 284, 148) | 14 | 12 | 18 | 7 |
| Basophils, High (n=268, 259, 278, 163) | 1 | 0 | 1 | 0 |
| Basophils, Low (n=269, 259, 278, 163) | 0 | 0 | 0 | 0 |
| Bilirubin Direct, High (n=295, 291, 307, 171) | 1 | 1 | 1 | 2 |
| Bilirubin Total, High (n=295, 290, 305, 168) | 2 | 4 | 4 | 1 |
| Calcitonin, High (n=226, 233, 230, 113) | 1 | 2 | 2 | 0 |
| Chloride, High (n=299, 293, 310, 174) | 0 | 1 | 0 | 0 |
| Chloride, Low (n=299, 293, 308, 174) | 1 | 2 | 1 | 1 |
| CPK, High (n=273, 262, 276, 156 | 29 | 20 | 30 | 7 |
| Creatinine, High (n=294, 285, 303, 172) | 7 | 10 | 5 | 5 |
| Creatinine Clearance, High (n=164, 186, 180, 107) | 17 | 28 | 26 | 25 |
| Creatinine Clearance, Low (n=292, 278,303,168) | 11 | 17 | 12 | 6 |
| Eosinophils, High (n=258, 256, 275, 157) | 4 | 11 | 6 | 2 |
| Eosinophils, Low (n=269, 259, 278, 163) | 0 | 0 | 0 | 0 |
| Erythrocyte Count, High (n=279, 272, 287, 164) | 1 | 1 | 0 | 0 |
| Erythrocyte Count, Low (n=274, 268, 280, 161) | 12 | 7 | 7 | 3 |
| GGT, High (n=234, 240, 245, 144) | 9 | 11 | 23 | 10 |
| Hematocrit, High (n=273, 265, 279, 161) | 1 | 1 | 1 | 2 |
| Hematocrit, Low (n=256, 242, 259, 157) | 13 | 10 | 6 | 5 |
| Hemoglobin, High (n=278, 271, 289, 164) | 1 | 1 | 1 | 2 |
| Hemoglobin, Low (n=262, 249, 265, 162) | 13 | 16 | 5 | 3 |
| Leukocyte Count, High (n=272, 265, 286, 165) | 3 | 6 | 1 | 0 |
| Leukocyte Count, Low (n=272, 262, 280, 165) | 2 | 3 | 4 | 1 |
| Lipase, High (n=255, 248, 269, 147) | 109 | 92 | 97 | 37 |
| Lymphocytes, High (n=249, 253, 269, 161) | 5 | 9 | 6 | 3 |
| Lymphocytes, Low (n=265, 258, 273, 159) | 3 | 3 | 4 | 2 |
| MCHC, High (n=274, 265, 280, 163) | 0 | 0 | 0 | 0 |
| MCHC, Low (n=273, 263, 279, 163) | 0 | 2 | 0 | 0 |
| MCV, High (n=261, 248, 263, 156) | 19 | 12 | 14 | 5 |
| MCV, Low (n=264, 252, 275, 162) | 3 | 2 | 2 | 0 |
| Monocytes, High (n=266, 258, 274, 163) | 1 | 0 | 3 | 1 |
| Monocytes, Low (n=265, 255, 274, 158) | 6 | 5 | 8 | 10 |
| Neutrophils, High (n=264, 255, 276, 161) | 4 | 5 | 3 | 1 |
| Neutrophils, Low (n=263, 251, 271, 162) | 2 | 1 | 2 | 1 |
| Platelet Count, High (n=265, 260, 281, 160) | 0 | 0 | 1 | 0 |
| Platelet Count, Low (n=262, 252, 269, 154) | 2 | 3 | 6 | 3 |
| Potassium, High (n=297, 291, 307, 172) | 7 | 2 | 5 | 4 |
| Potassium, Low (n=298, 293, 308, 169) | 4 | 6 | 3 | 1 |
| Sodium, High (n=291, 291, 307, 170) | 3 | 4 | 4 | 4 |
| Sodium, Low (n=298, 292, 305, 174) | 2 | 1 | 4 | 1 |
| Urea Nitrogen, High (n=287, 282, 305, 169) | 11 | 17 | 13 | 5 |
| UMCR, High (n=217, 204, 232, 130) | 18 | 9 | 13 | 5 |
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR) .
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin |
|---|---|---|---|
| Alkaline Phosphatase, High (n=276, 258, 281) | 10 | 6 | 16 |
| ALT/SGPT, High (n=232, 237, 244) | 25 | 27 | 28 |
| Amylase Pancreatic, High (n=283, 277, 295) | 67 | 70 | 55 |
| Amylase Total, High (n=266, 265, 277) | 38 | 42 | 36 |
| AST/SGOT, High (n=273, 269, 284) | 15 | 19 | 25 |
| Basophils, High (n=276, 268, 287) | 1 | 0 | 1 |
| Basophils, Low (n=277, 268, 287) | 0 | 0 | 0 |
| Bilirubin Direct, High (n=295, 291, 307) | 1 | 1 | 2 |
| Bilirubin Total, High (n=295, 290, 305) | 2 | 6 | 5 |
| Calcitonin, High (n=233, 239, 235) | 4 | 2 | 2 |
| Chloride, High (n=299, 293, 310) | 0 | 1 | 0 |
| Chloride, Low (n=299, 293, 308) | 1 | 2 | 2 |
| CPK, High (n=273, 262, 276) | 38 | 28 | 43 |
| Creatinine, High (n=294, 285, 303) | 9 | 10 | 6 |
| Creatinine Clearance, High (n=164, 186, 180) | 23 | 30 | 29 |
| Creatinine Clearance, Low (n=292, 278, 303) | 18 | 20 | 15 |
| Eosinophils, High (n=265, 265, 283) | 11 | 14 | 10 |
| Eosinophils, Low (n=277, 268, 287) | 0 | 0 | 0 |
| Erythrocyte Count, High (n=283, 276, 292) | 3 | 1 | 1 |
| Erythrocyte Count, Low (n=278, 272, 285) | 15 | 9 | 11 |
| GGT, High (n=234, 240, 245) | 10 | 14 | 34 |
| Hematocrit, High (n=280, 274, 290) | 3 | 2 | 2 |
| Hematocrit, Low (n=262, 251, 269) | 21 | 13 | 11 |
| Hemoglobin, High (n=282, 275, 294) | 3 | 1 | 1 |
| Hemoglobin, Low (n=265, 253, 269) | 21 | 19 | 11 |
| Leukocyte Count, High (n=277, 270, 292) | 7 | 6 | 3 |
| Leukocyte Count, Low (n=277, 267, 284) | 5 | 3 | 9 |
| Lipase, High (n=255, 248, 269) | 124 | 111 | 110 |
| Lymphocytes, High (n=257, 262, 278) | 12 | 15 | 11 |
| Lymphocytes, Low (n=273, 266, 280) | 4 | 4 | 11 |
| MCHC, High (n=281, 274, 291) | 0 | 0 | 0 |
| MCHC, Low (n=280, 272, 290) | 2 | 3 | 3 |
| MCV, High (n=267, 256, 273) | 25 | 18 | 19 |
| MCV, Low (n=270, 261, 286) | 3 | 2 | 4 |
| Monocytes, High (n=274, 267, 283) | 1 | 0 | 5 |
| Monocytes, Low (n=271, 264, 282) | 8 | 9 | 15 |
| Neutrophils, High (n=272, 263, 285) | 8 | 7 | 7 |
| Neutrophils, Low (n=271, 260, 279) | 6 | 2 | 6 |
| Platelet Count, High (n=272, 267, 287) | 0 | 2 | 2 |
| Platelet Count, Low (n=269, 259, 275) | 4 | 5 | 8 |
| Potassium, High (n=297, 291, 307) | 10 | 5 | 5 |
| Potassium, Low (n=298, 293, 308) | 6 | 7 | 5 |
| Sodium, High (n=291, 291, 307) | 5 | 8 | 4 |
| Sodium, Low (n=298, 292, 305) | 3 | 1 | 4 |
| Urea Nitrogen, High (n=287, 282, 305) | 14 | 19 | 21 |
| UMCR, High (n=223, 212, 238) | 33 | 21 | 18 |
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin |
|---|---|---|---|
| Alkaline Phosphate, High (n=276, 258, 281) | 13 | 11 | 20 |
| ALT/SGPT, High (n=232, 237, 244) | 29 | 37 | 39 |
| Amylase Pancreatic, High (n=283, 277, 295) | 81 | 78 | 61 |
| Amylase Total, High (n=266, 265, 277) | 44 | 55 | 43 |
| AST/SGOT, High (n=273, 269, 284) | 21 | 27 | 36 |
| Basophils, High (n=276, 268, 288) | 1 | 0 | 1 |
| Basophils, Low (n=277, 268, 288) | 0 | 0 | 0 |
| Bilirubin Direct, High (n=295, 291, 307) | 2 | 1 | 3 |
| Bilirubin Total, High (n=295, 290, 305) | 3 | 8 | 6 |
| Calcitonin, High (n=233, 239, 235) | 5 | 3 | 4 |
| Chloride, High (n=299, 293, 310) | 0 | 2 | 1 |
| Chloride, Low (n=299, 293, 308) | 3 | 2 | 3 |
| CPK, High (n=273, 262, 276) | 52 | 41 | 54 |
| Creatinine, High (n=294, 285, 303) | 11 | 16 | 9 |
| Creatinine Clearance, High (n=164, 186, 180) | 26 | 32 | 34 |
| Creatinine Clearance, Low (n=292, 278, 303) | 24 | 25 | 20 |
| Eosinophils, High (n=265, 265, 284) | 12 | 22 | 14 |
| Eosinophils, Low (n=277, 268, 288) | 0 | 0 | 0 |
| Erythrocyte Count, High (n=283, 276, 292) | 3 | 2 | 1 |
| Erythrocyte Count, Low (n=278, 272, 285) | 18 | 14 | 19 |
| GGT, High (n=234, 240, 245) | 16 | 24 | 45 |
| Hematocrit, High (n=280, 274, 290) | 3 | 6 | 3 |
| Hematocrit, Low (n=262, 251, 269) | 30 | 24 | 29 |
| Hemoglobin, High (n=282, 275, 294) | 4 | 3 | 2 |
| Hemoglobin, Low (n=265, 253, 269) | 30 | 28 | 25 |
| Leukocyte Count, High (n=277, 270, 292) | 13 | 9 | 8 |
| Leukocyte Count, Low (n=277, 267, 284) | 9 | 7 | 14 |
| Lipase, High (n=255, 248, 269) | 142 | 132 | 126 |
| Lymphocytes, High (n=257, 262, 279) | 19 | 20 | 21 |
| Lymphocytes, Low (n=273, 266, 281) | 5 | 9 | 12 |
| MCHC, High (n=281, 274, 291) | 0 | 0 | 0 |
| MCHC, Low (n=280, 272, 290) | 5 | 4 | 5 |
| MCV, High (n=267, 256, 273) | 39 | 25 | 25 |
| MCV, Low (n=270, 261, 286) | 9 | 3 | 4 |
| Monocytes, High (n=274, 267, 284) | 3 | 1 | 11 |
| Monocytes, Low (n=271, 264, 283) | 10 | 14 | 17 |
| Neutrophils, High (n=272, 263, 286) | 15 | 12 | 13 |
| Neutrophils, Low (n=271, 260, 280) | 10 | 6 | 10 |
| Platelet Count, High (n=273, 268, 287) | 2 | 3 | 3 |
| Platelet Count, Low (n=270, 260, 275) | 8 | 7 | 8 |
| Potassium, High (n=297, 291, 307) | 14 | 9 | 8 |
| Potassium, Low (n=298, 293, 308) | 8 | 8 | 5 |
| Sodium, High (n=291, 291, 307) | 10 | 10 | 6 |
| Sodium, Low (n=298, 292, 305) | 5 | 1 | 5 |
| Urea Nitrogen, High (n=287, 282, 305) | 17 | 29 | 29 |
| UMCR, High (n=223, 212, 239) | 38 | 27 | 30 |
The number of participants with treatment-emergent abnormal lipid test (cholesterol, high density lipoprotein cholesterol \[HDL-C\], low density lipoprotein cholesterol \[LDL-C\], and triglycerides \[TG\]) results (defined as lipid test abnormalities that first occurred after baseline) is summarized cumulatively.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| Cholesterol, High, 26 Weeks (n=144, 158, 139, 58) | 16 | 21 | 20 | 8 |
| Cholesterol, High, 104 Weeks (n=151, 164, 146) | 34 | 29 | 34 | NA |
| HDL-C, High, 26 Weeks (n=197, 201, 189, 78) | 1 | 0 | 0 | 0 |
| HDL-C, Low, 26 Weeks (n=127, 137, 129, 52) | 9 | 13 | 8 | 1 |
| HDL-C, High, 104 Weeks (n=206, 212, 199) | 2 | 1 | 2 | NA |
| HDL-C, Low, 104 Weeks (n=134, 143, 138) | 13 | 20 | 13 | NA |
| LDL-C, High, 26 Weeks (n=155, 163, 150, 61) | 15 | 11 | 19 | 7 |
| LDL-C, High, 104 Weeks (n=163, 170, 157) | 31 | 23 | 29 | NA |
| TG, High, 26 Weeks (n=163, 174, 156, 64) | 6 | 13 | 10 | 2 |
| TG, High, 104 Weeks (n=170, 183, 166) | 13 | 22 | 15 | NA |
Sitting pulse rate was measured at the time that the dose decision was made (dose decision point). Change from baseline in pulse rate was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.
| beats per minute (bpm) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Pulse Rate at Dose Decision Point | 6.63 ± 7.28 | 3.43 ± 10.14 | 2.39 ± 7.88 | 3.34 ± 9.88 | -1.63 ± 8.03 | 1.91 ± 6.18 | 1.05 ± 9.44 | -0.16 ± 8.07 | 1.81 ± 7.90 |
Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at the dose decision point. Change from baseline in DBP was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the time of the decision point was 27.4 weeks.
| millimeters of mercury (mmHg) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|---|---|---|---|---|
| Sitting SBP | -8.85 ± 12.92 | -4.63 ± 15.28 | -4.77 ± 11.37 | -2.00 ± 9.94 | -6.21 ± 19.13 | 0.40 ± 11.51 | 1.67 ± 10.18 | -2.16 ± 10.62 | -0.61 ± 14.75 |
| Sitting DBP | -1.21 ± 7.47 | -1.17 ± 6.32 | -1.20 ± 4.67 | -0.08 ± 8.00 | -3.18 ± 10.13 | -0.75 ± 7.99 | 1.28 ± 4.06 | -1.11 ± 6.65 | -0.22 ± 7.94 |
Sitting and standing pulse rate were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as covariate.
| beats per minute (bpm) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| Sitting, 26 Weeks (n=271, 278, 283, 138) | 2.57 ± 0.47 | 1.90 ± 0.47 | -0.11 ± 0.46 | -0.22 ± 0.65 |
| Sitting, 104 Weeks (n=197, 192, 191) | 2.28 ± 0.53 | 2.77 ± 0.54 | -0.78 ± 0.53 | NA ± NA |
| Standing, 26 Weeks (n=271, 277, 281, 138) | 3.24 ± 0.52 | 2.00 ± 0.52 | -0.24 ± 0.51 | -0.17 ± 0.71 |
| Standing, 104 Weeks (n=197, 192, 191) | 2.26 ± 0.63 | 2.50 ± 0.64 | -1.06 ± 0.63 | NA ± NA |
Sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| millimeters of mercury (mmHg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| Sitting SBP, 26 Weeks (n=271, 278, 283, 138) | -1.73 ± 0.67 | -1.40 ± 0.67 | -1.94 ± 0.66 | 1.12 ± 0.92 |
| Sitting SBP, 104 Weeks (n=197, 192, 191) | -0.07 ± 0.81 | 1.28 ± 0.82 | 0.02 ± 0.82 | NA ± NA |
| Sitting DBP, 26 Weeks (n=271, 278, 283, 138) | -0.43 ± 0.43 | -0.20 ± 0.43 | -1.06 ± 0.42 | 0.68 ± 0.58 |
| Sitting DBP, 104 Weeks (n=197, 192, 191) | 0.38 ± 0.52 | 1.40 ± 0.52 | -0.36 ± 0.52 | NA ± NA |
| Standing SBP, 26 Weeks (n=271, 277, 281, 138) | -1.53 ± 0.76 | -1.72 ± 0.76 | -2.54 ± 0.74 | 0.26 ± 1.04 |
| Standing SBP, 104 Weeks (n=197, 192, 191) | -1.30 ± 0.92 | 0.17 ± 0.93 | -1.20 ± 0.92 | NA ± NA |
| Standing DBP, 26 Weeks (n=271, 277, 281, 138) | -0.11 ± 0.48 | 0.03 ± 0.48 | -1.36 ± 0.47 | -0.52 ± 0.66 |
| Standing DBP, 104 Weeks (n=197, 192, 191) | -0.23 ± 0.57 | 0.36 ± 0.58 | -0.67 ± 0.58 | NA ± NA |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| milliseconds (msec) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) |
|---|---|---|---|---|
| PR Interval, 26 Weeks (n=256, 261, 268, 132) | 2.94 ± 0.66 | 1.60 ± 0.66 | 0.42 ± 0.65 | 2.24 ± 0.89 |
| PR Interval, 104 Weeks (n=168, 170, 167) | 4.59 ± 0.90 | 3.06 ± 0.90 | 3.19 ± 0.90 | NA ± NA |
| QTcF Interval, 26 Weeks (n=258, 262, 268, 132) | -3.86 ± 0.75 | -2.44 ± 0.75 | -1.31 ± 0.73 | 1.76 ± 1.02 |
| QTcF Interval, 104 Weeks (n=169, 170, 168) | -2.71 ± 0.84 | -2.49 ± 0.84 | -0.02 ± 0.83 | NA ± NA |
The Impact of Weight on Quality of Life-Lite (IWQoL-Lite questionnaire) is an obesity-specific, 31-item questionnaire designed to measure the impact of weight on participants' quality of life. Items are scored on a 5-point numeric rating scale where 5 = "always true" and 1 = "never true". Items are summed into 6 scales (physical function \[11 items\], self-esteem \[7 items\], sexual life \[4 items\], public distress \[5 items\], work \[4 items\], and total score \[31 items\]) based on the average for the valid responses on that scale multiplied by the number of items on that scale (rounded to the nearest whole integer). Higher scores indicate lower levels of functioning (negative effects). Scores are linearly transformed to a 0 to 100 scale.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin |
|---|---|---|---|
| Total Score, Baseline (n=285, 284, 300) | 83.41 ± 16.031 | 82.55 ± 16.952 | 83.97 ± 16.514 |
| Total Score, 52 Weeks (n=237, 252, 247) | 86.92 ± 14.972 | 86.31 ± 14.673 | 86.25 ± 15.628 |
| Total Score, 104 Weeks (n=190, 190, 185) | 88.08 ± 15.555 | 87.47 ± 15.183 | 86.93 ± 16.304 |
The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts. The first part allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a three level scale of 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the questionnaire consists of a 100-millimeter visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health state).
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin |
|---|---|---|---|
| EQ-5D, UK, Baseline (n=285, 281, 300) | 0.80 ± 0.222 | 0.82 ± 0.223 | 0.84 ± 0.216 |
| EQ-5D, UK, 52 Weeks (n=237, 250, 244) | 0.83 ± 0.211 | 0.84 ± 0.208 | 0.85 ± 0.210 |
| EQ-5D, UK, 104 Weeks (n=189, 190, 185) | 0.84 ± 0.203 | 0.86 ± 0.184 | 0.86 ± 0.198 |
| VAS, Baseline (n=285, 284, 301) | 75.57 ± 15.798 | 75.35 ± 16.001 | 76.85 ± 15.363 |
| VAS, 52 Weeks (n=238, 251, 245) | 78.93 ± 13.352 | 78.22 ± 13.839 | 78.79 ± 14.567 |
| VAS, 104 Weeks (n=189, 190, 185) | 79.66 ± 13.820 | 78.52 ± 14.114 | 81.34 ± 13.708 |
The number of visits to the emergency room (ER) is summarized cumulatively.
| events | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Sitagliptin |
|---|---|---|---|
| 52 Weeks | NA | NA | NA |
| 104 Weeks | NA | NA | NA |
Pharmacokinetic (PK) parameter estimates from LY2189265 concentration data were obtained using a 2-compartment population PK model with first order absorption. Area under the plasma-concentration curve from 0 to 168 hours, steady state (AUC0-168h, ss) of LY2189265 is summarized.
| nanograms times hours per milliliter | 1.5 mg LY2189265 | 0.75 mg LY2189265 |
|---|---|---|
| Pharmacokinetics of LY2189265: Area Under the Concentration-Time Curve | 13378 ± 6100 | 7246 ± 3304 |
The number of participants with postbaseline detection of treatment-emergent antidrug LY2189265 antibodies (ADA) is summarized.
| participants | LY2189265 |
|---|---|
| Antibodies to LY2189265 | 9 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) | Placebo/Sitagliptin (26 Weeks Through 104 Weeks) |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adjudicated Pancreatitis at 104 Weeks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
Data on any new cardiovascular (CV) event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 26 Weeks) | Placebo/Sitagliptin (26 Weeks Through 104 Weeks) |
|---|---|---|---|---|---|---|---|---|---|---|
| Participants With Any CV Event | 0 | 0 | 6 | 0 | 4 | 0 | 0 | 5 | 0 | 3 |
| Participants With a Fatal CV Event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Participants With a Non-fatal CV Event | 0 | 0 | 6 | 0 | 4 | 0 | 0 | 4 | 0 | 2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3.0 mg LY2189265 | — | 1/15 (6.7%) | 9/15 (60%) |
| 2.0 mg LY2189265 | — | 1/30 (3.3%) | 20/30 (66.7%) |
| 1.5 mg LY2189265 | — | 36/304 (11.8%) | 252/304 (82.9%) |
| 1.0 mg LY2189265 | — | 0/10 (0%) | 8/10 (80%) |
| 0.75 mg LY2189265 | — | 23/302 (7.6%) | 255/302 (84.4%) |
| 0.5 mg LY2189265 | — | 1/25 (4%) | 15/25 (60%) |
| 0.25 mg LY2189265 | — | 0/24 (0%) | 10/24 (41.7%) |
| Sitagliptin | — | 32/315 (10.2%) | 239/315 (75.9%) |
| Placebo/Sitagliptin (Baseline Through 104 Weeks) | — | 17/177 (9.6%) | 138/177 (78%) |
| Event | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 104 Weeks) |
|---|---|---|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/15 | 0/30 | 0/304 | 0/10 | 0/302 | 0/25 | 0/24 | 1/315 | 0/177 |
| PneumoniaInfections and infestations | 0/15 | 0/30 | 0/304 | 0/10 | 0/302 | 1/25 | 0/24 | 2/315 | 0/177 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 1/30 | 1/304 | 0/10 | 0/302 | 0/25 | 0/24 | 0/315 | 0/177 |
| Cervical dysplasiaReproductive system and breast disorders | 0/10 | 0/22 | 0/158 | 0/7 | 0/168 | 0/12 | 0/15 | 0/164 | 1/87 |
| Myocardial infarctionCardiac disorders | 0/15 | 0/30 | 2/304 | 0/10 | 0/302 | 0/25 | 0/24 | 1/315 | 2/177 |
| Blood calcitonin increasedInvestigations | 0/15 | 0/30 | 0/304 | 0/10 | 3/302 | 0/25 | 0/24 | 0/315 | 0/177 |
| Prostatic adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 0/8 | 1/146 | 0/3 | 1/134 | 0/13 | 0/9 | 0/151 | 0/90 |
| Urinary tract infectionInfections and infestations | 0/15 | 0/30 | 0/304 | 0/10 | 2/302 | 0/25 | 0/24 | 0/315 | 0/177 |
| FallInjury, poisoning and procedural complications | 0/15 | 0/30 | 2/304 | 0/10 | 2/302 | 0/25 | 0/24 | 0/315 | 0/177 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/5 | 0/8 | 0/146 | 0/3 | 0/134 | 0/13 | 0/9 | 1/151 | 0/90 |
| Event | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin (Baseline Through 104 Weeks) |
|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/15 | 6/30 | 53/304 | 4/10 | 44/302 | 3/25 | 2/24 | 22/315 | 9/177 |
| GastritisGastrointestinal disorders | 0/15 | 1/30 | 11/304 | 2/10 | 4/302 | 0/25 | 0/24 | 9/315 | 7/177 |
| VomitingGastrointestinal disorders | 2/15 | 4/30 | 41/304 | 2/10 | 25/302 | 1/25 | 1/24 | 11/315 | 3/177 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 5/30 | 50/304 | 1/10 | 36/302 | 4/25 | 2/24 | 18/315 | 15/177 |
| NasopharyngitisInfections and infestations | 0/15 | 1/30 | 43/304 | 0/10 | 48/302 | 1/25 | 0/24 | 47/315 | 25/177 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/15 | 0/30 | 30/304 | 0/10 | 38/302 | 0/25 | 0/24 | 49/315 | 28/177 |
| GastroenteritisInfections and infestations | 2/15 | 0/30 | 12/304 | 0/10 | 7/302 | 1/25 | 0/24 | 6/315 | 7/177 |
| ConstipationGastrointestinal disorders | 1/15 | 0/30 | 14/304 | 0/10 | 16/302 | 3/25 | 0/24 | 4/315 | 1/177 |
| DyspepsiaGastrointestinal disorders | 0/15 | 1/30 | 18/304 | 1/10 | 19/302 | 3/25 | 1/24 | 16/315 | 4/177 |
| Visual acuity reducedEye disorders | 0/15 | 0/30 | 1/304 | 1/10 | 0/302 | 0/25 | 0/24 | 0/315 | 0/177 |
All randomized participants.
| Age, Continuous(years) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.81 ± 10.66 | 52.56 ± 10.95 | 53.66 ± 10.02 | 55.38 ± 8.71 | 54.35 ± 9.81 | 54.70 ± 9.72 | 56.51 ± 6.56 | 53.75 ± 10.27 | 54.91 ± 9.05 | 54.09 ± 9.85 |
| Sex: Female, Male(Participants) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 10 | 22 | 158 | 7 | 168 | 12 | 15 | 164 | 87 | 643 |
| Male | 5 | 8 | 146 | 3 | 134 | 13 | 9 | 151 | 90 | 559 |
| Race/Ethnicity, Customized(participants) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Aboriginal and/or Torres Strait Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| African | 1 | 3 | 16 | 0 | 12 | 2 | 0 | 7 | 9 | 50 |
| Caucasian | 7 | 13 | 157 | 4 | 162 | 9 | 12 | 158 | 91 | 613 |
| East Asian | 0 | 6 | 50 | 0 | 47 | 0 | 5 | 52 | 28 | 188 |
| Hispanic | 7 | 8 | 54 | 6 | 51 | 14 | 6 | 67 | 38 | 251 |
| Native American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| West Asian (Indian sub-continent) | 0 | 0 | 27 | 0 | 30 | 0 | 1 | 28 | 11 | 97 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | 9 | 17 | 73 | 4 | 83 | 10 | 7 | 80 | 46 | 329 |
| Taiwan | 0 | 1 | 19 | 0 | 18 | 0 | 3 | 20 | 12 | 73 |
| Spain | 0 | 0 | 10 | 0 | 11 | 0 | 0 | 11 | 4 | 36 |
| Russian Federation | 0 | 0 | 21 | 0 | 18 | 0 | 0 | 17 | 8 | 64 |
| India | 0 | 0 | 27 | 0 | 29 | 0 | 0 | 28 | 12 | 96 |
| France | 0 | 0 | 12 | 0 | 14 | 0 | 0 | 12 | 8 | 46 |
| Mexico | 3 | 3 | 32 | 5 | 30 | 10 | 6 | 35 | 27 | 151 |
| Puerto Rico | 1 | 2 | 12 | 0 | 5 | 3 | 0 | 10 | 7 | 40 |
| Canada | 0 | 0 | 13 | 0 | 11 | 0 | 0 | 12 | 6 | 42 |
| Poland | 1 | 0 | 20 | 0 | 23 | 2 | 2 | 23 | 12 | 83 |
| Romania | 1 | 2 | 7 | 1 | 4 | 0 | 4 | 8 | 5 | 32 |
| Germany | 0 | 0 | 31 | 0 | 31 | 0 | 0 | 28 | 15 | 105 |
| Korea, Republic of | 0 | 5 | 27 | 0 | 25 | 0 | 2 | 31 | 15 | 105 |
| Body Weight(kilograms) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 85.09 ± 14.25 | 86.56 ± 18.33 | 86.67 ± 17.45 | 89.48 ± 18.06 | 86.22 ± 17.99 | 88.84 ± 14.98 | 81.94 ± 17.67 | 85.97 ± 16.91 | 87.07 ± 16.86 | 86.38 ± 17.28 |
| Body Mass Index (BMI)(kilograms per square meter (kg/m^2)) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 31.02 ± 4.69 | 31.45 ± 4.88 | 31.40 ± 4.57 | 33.89 ± 4.44 | 31.15 ± 4.44 | 32.53 ± 4.61 | 31.06 ± 3.94 | 31.02 ± 4.20 | 31.37 ± 4.25 | 31.27 ± 4.39 |
| Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 7.95 ± 1.11 | 8.36 ± 1.04 | 8.12 ± 1.05 | 7.87 ± 0.62 | 8.19 ± 1.11 | 8.30 ± 1.34 | 7.82 ± 0.80 | 8.09 ± 1.09 | 8.10 ± 1.14 | 8.13 ± 1.09 |
| Duration of Diabetes(years) | 3.0 mg LY2189265 | 2.0 mg LY2189265 | 1.5 mg LY2189265 | 1.0 mg LY2189265 | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Sitagliptin | Placebo/Sitagliptin | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 6.79 ± 6.34 | 6.92 ± 5.12 | 6.95 ± 5.50 | 7.04 ± 4.57 | 7.34 ± 4.92 | 6.75 ± 3.99 | 6.74 ± 4.20 | 7.16 ± 4.89 | 6.96 ± 5.43 | 7.09 ± 5.12 |
1 further baseline measures are reported on the registry.
The record gives a start of Aug 2008, a primary completion of Jun 2011 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 3 years 7 months after primary completion. A results delay was requested in Sep 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide